---
title: "“老药新用”，利用PRISM筛选非肿瘤药物的抗癌活性"
date: 2024-08-09T02:24:30Z
draft: ["false"]
tags: [
  "fetched",
  "肺鳞癌"
]
categories: ["Acdemic"]
---
“老药新用”，利用PRISM筛选非肿瘤药物的抗癌活性 by 肺鳞癌
------
<div><section data-mpa-powered-by="yiban.io"><section powered-by="xiumi.us"><p>撰稿 | 袁增壮</p><p>责编 | 刘坚 高斐然</p><p><br></p></section><section powered-by="xiumi.us"><section><section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section></section><section><section powered-by="xiumi.us"><section><section><section powered-by="xiumi.us"><section><img data-ratio="0.1503268" data-src="https://mmbiz.qpic.cn/sz_mmbiz_gif/MVPvEL7Qg0Egj76lSPicXbCTgBVIialdvwWxbm21OZytaf8P6xK86NglUjbFn8agwwLkdNhBNdSRvMLtiaXKjEj7A/640?wx_fmt=gif" data-type="gif" data-w="306" width="100%" src="https://mmbiz.qpic.cn/sz_mmbiz_gif/MVPvEL7Qg0Egj76lSPicXbCTgBVIialdvwWxbm21OZytaf8P6xK86NglUjbFn8agwwLkdNhBNdSRvMLtiaXKjEj7A/640?wx_fmt=gif"></section></section></section></section></section></section><section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section></section></section></section><section powered-by="xiumi.us"><p><span>2020年2月，美国麻省理工学院和哈佛大学博德研究所的</span><span><strong>Todd R. Golub</strong></span><span>团队在</span><span><em><strong>Nature Cancer</strong></em></span><span>上发表题为</span><span><em><span><strong>“Discovering the anticancer potential of non-oncology drugs by systematic viability profiling”</strong></span></em></span><span>的文章，该研究使用分子条形码方法</span><span><strong>PRISM(profiling relative inhibition simultaneously in mixtures)</strong></span><span>筛选针对</span><span><strong>578</strong></span><span>种人类癌细胞系的</span><span><strong>4518</strong></span><span>种非癌症药物的抑癌活性，发现了近</span><span><strong>50</strong></span><span>种药物存在先前无法识别出来的抗癌活性，同时开发了一个包含大量非肿瘤药物抗癌活性资源的PRISM再利用数据集，并建立了PRISM药物再利用资源作为新肿瘤疗法的起点。</span></p><section><img data-cropselx1="0" data-cropselx2="578" data-cropsely1="0" data-cropsely2="207" data-ratio="0.5478821362799263" data-src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEezHzjIibDgDNZaPib9ia2sDHmiasbjYoKI8IsRQtZ3cBbPuB9bIdwFnicaOg/640?wx_fmt=png" data-type="png" data-w="1086" src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEezHzjIibDgDNZaPib9ia2sDHmiasbjYoKI8IsRQtZ3cBbPuB9bIdwFnicaOg/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><section><section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section></section><section><section powered-by="xiumi.us"><section><section><section powered-by="xiumi.us"><section><img data-ratio="0.1503268" data-src="https://mmbiz.qpic.cn/sz_mmbiz_gif/MVPvEL7Qg0Egj76lSPicXbCTgBVIialdvwWxbm21OZytaf8P6xK86NglUjbFn8agwwLkdNhBNdSRvMLtiaXKjEj7A/640?wx_fmt=gif" data-type="gif" data-w="306" width="100%" src="https://mmbiz.qpic.cn/sz_mmbiz_gif/MVPvEL7Qg0Egj76lSPicXbCTgBVIialdvwWxbm21OZytaf8P6xK86NglUjbFn8agwwLkdNhBNdSRvMLtiaXKjEj7A/640?wx_fmt=gif"></section></section></section></section></section></section><section><section powered-by="xiumi.us"><section><span></span><br></section></section></section></section></section><section powered-by="xiumi.us"><p><span>抗癌新药的研究开发存在耗时长、风险高等棘手问题，难以及时满足临床用药需求，因而转变现有药物的用途以适应新的临床适应症前景诱人，一方面是因为这些在人类身上已被证明安全的药物可进行快速的临床转化，另一方面，现有药物可在发现新靶点时作为新药研发的起点。然而，目前筛选出的具有抗癌作用的非肿瘤药物数量少且发现过程具有偶然性，先前采取的筛选方式包括在有限数量的细胞系中测试多种化合物，以及在多种细胞系中测试少量肿瘤学化合物，而针对整个药典进行大规模系统的筛选仍难以实现，使得<strong>非肿瘤药物用于未来治疗癌症的潜力被低估</strong>。</span></p><section><span>为了可以在每个培养皿中聚集多种细胞系，更快进行较大规模的药物筛选实验，该团队利用PRISM方法，将涵盖24种肿瘤类型的578个贴壁细胞系用DNA条形码进行了标记，并从药物再利用中心</span><span><strong>(Drug Repurposing Hub)</strong></span><span>选择了4518种药物。作者采取两阶段筛选策略，即首先在2.5μM单次剂量下对所有药物进行初步筛选，然后对1448种活性药物进行8个剂量的再测试，研究者发现1448种中绝大部分活性化合物最初是为非肿瘤临床适应症开发的。作者将PRISM结果与癌症药物敏感性基因组学数据库</span><span><strong>(GDSC)</strong></span><span>、癌症靶点发现与开发数据库</span><span><strong>(CTD2)</strong></span><span>进行了比较，结果表明，尽管测定形式，化合物来源和细胞系来源有所不同，但PRISM再利用数据集与现有药物基因组数据集相比具有相似稳健性</span><span>（图一）</span><span>。</span></section><section><img data-backh="328" data-backw="578" data-cropselx1="0" data-cropselx2="578" data-cropsely1="0" data-cropsely2="401" data-galleryid="" data-ratio="0.5672624647224835" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEejU0addGD2LTCtjpBnXtbs8zxjwnNdnIBgut8LMkGvTKkgAy1WK6iadQ/640?wx_fmt=png" data-type="png" data-w="1063" src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEejU0addGD2LTCtjpBnXtbs8zxjwnNdnIBgut8LMkGvTKkgAy1WK6iadQ/640?wx_fmt=png"><img data-backh="228" data-backw="578" data-cropselx1="0" data-cropselx2="578" data-cropsely1="0" data-cropsely2="328" data-galleryid="" data-ratio="0.3945818610129564" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEeVqR2uaEjMphKM3aZUiagEoWxgZBIuOb71ibThF907a8tXwAem35w8wcA/640?wx_fmt=png" data-type="png" data-w="849" src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEeVqR2uaEjMphKM3aZUiagEoWxgZBIuOb71ibThF907a8tXwAem35w8wcA/640?wx_fmt=png"><img data-backh="59" data-backw="578" data-cropselx1="36" data-cropselx2="322" data-cropsely1="0" data-cropsely2="29" data-galleryid="" data-ratio="0.0810126582278481" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEe96dMiaNSR1UPjdxFCuJqRrMgK37AVLkto9920gXBUlvpKdibOVV8uttg/640?wx_fmt=png" data-type="png" data-w="395" src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEe96dMiaNSR1UPjdxFCuJqRrMgK37AVLkto9920gXBUlvpKdibOVV8uttg/640?wx_fmt=png"><span></span></section><p><span><span></span></span><span>图一：</span><span>PRISM</span><span>再利用数据集生成示意图及其数据与参考数据的比较</span><span></span></p><section><span>该团队为了研究非肿瘤药物对癌症生存能力的影响，使用统一流形逼近与投影<strong>(UMAP)</strong>方法对独立于功能注释的化合物生存能力谱进行无监督聚类，结果显示具有相似作用机理的化合物趋于聚集在一起，这表明PRISM分析恢复了预期的活性。为进一步研究非肿瘤药物的治疗潜力，该研究团队计算了每种化合物剂量生存力曲线的双峰系数及其最大值，发现尽管非肿瘤药物的平均双峰性低于癌症药物，但数据集中最具选择性的化合物包括非肿瘤药物。<strong>这进一步证明对非癌药物进行大规模测试可揭示其选择性的抗癌活性</strong></span><span>（图二）</span><span>。</span><span></span></section><section><img data-backh="260" data-backw="466" data-cropselx1="0" data-cropselx2="578" data-cropsely1="0" data-cropsely2="313" data-galleryid="" data-ratio="0.5583424209378408" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEebNrN3S5ibpUUehRPL3wo0fUJElWIPCOMyVfdqUOua7BribhX76W3elqg/640?wx_fmt=png" data-type="png" data-w="917" src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEebNrN3S5ibpUUehRPL3wo0fUJElWIPCOMyVfdqUOua7BribhX76W3elqg/640?wx_fmt=png"><img data-backh="370" data-backw="578" data-cropselx1="0" data-cropselx2="578" data-cropsely1="0" data-cropsely2="370" data-galleryid="" data-ratio="0.6406926406926406" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEeIrSfe4Reduqqt1G2tib2wvxqxscicYZTPvUSDtibvhgKGokCxmzMuiaCzA/640?wx_fmt=png" data-type="png" data-w="462" src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEeIrSfe4Reduqqt1G2tib2wvxqxscicYZTPvUSDtibvhgKGokCxmzMuiaCzA/640?wx_fmt=png"></section><p><span></span><span>图</span><span>二</span><span>：</span><span>非肿瘤学药物对</span><span>癌症生存能力的影响</span><span></span><br></p><section><span>接着该团队基于细胞系的基因组特征研究了可预测的细胞杀伤活性范围，利用<strong>ATLANTIS</strong>算法发现，与化疗药物或非肿瘤药物相比，除了大多数高度可预测的杀伤谱来自靶向肿瘤药物这一正常现象，作者还观察到大量的非肿瘤药物同样具有高度可预测的杀伤模式。此外，相比于其他类别的基因组信息，mRNA表达是最具预测性的分子特征类型，与其他药物基因组筛选和基于短发夹状RNA的功能基因组筛选的结果一致。在初级筛选中，有195种非肿瘤药物具有可预测的杀伤力(Pearson &gt; 0.2)，有23种具有Pearson &gt; 0.4的可预测杀伤力。当可预测性与双峰性评分作图时，观察到同样高度可预测的非肿瘤性药物杀伤现象。例如，作者通过PRISM发现，许多非肿瘤药物可以通过诱导磷酸二酯酶3A<strong>(PDE3A)</strong>与<strong>Schlafen</strong>蛋白家族<strong>(SLFN)</strong>成员<strong>SLFN12</strong>形成PDE3A-SLFN12复合物，进而杀死表达PDE3A的癌细胞。这些非肿瘤药物抗癌效力虽然有限，但根据其抗癌机制对药物虽然进行优化，可能会产生更有效/更具选择性的新抗癌候选药物</span><span>（图三）</span><span>。</span></section><section><span><br></span><span></span><img data-backh="253" data-backw="578" data-cropselx1="0" data-cropselx2="578" data-cropsely1="0" data-cropsely2="234" data-galleryid="" data-ratio="0.4371700105596621" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEeT9ibiaFsPMdXu1ZYw8UicJCFXnicpcNL3XARKBev4Esqc0kFFWeO8CDsvw/640?wx_fmt=png" data-type="png" data-w="947" src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEeT9ibiaFsPMdXu1ZYw8UicJCFXnicpcNL3XARKBev4Esqc0kFFWeO8CDsvw/640?wx_fmt=png"><img data-backh="337" data-backw="578" data-cropselx1="0" data-cropselx2="578" data-cropsely1="0" data-cropsely2="764" data-galleryid="" data-ratio="0.5815268614514609" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEeiaTuT8CWP0UlQt0EJBxZzZib48QADrTlzAgbW6aJlZGLiaQNAIA9A0DOQ/640?wx_fmt=png" data-type="png" data-w="1061" src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEeiaTuT8CWP0UlQt0EJBxZzZib48QADrTlzAgbW6aJlZGLiaQNAIA9A0DOQ/640?wx_fmt=png"><img data-backh="328" data-backw="578" data-cropselx1="0" data-cropselx2="578" data-cropsely1="0" data-cropsely2="336" data-galleryid="" data-ratio="0.5671641791044776" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEeWGM0iaTZLf1ibwrbGIpESDnhyz4PicBUnfmM4sYA4Gxicr6HMCfc6EN9Ww/640?wx_fmt=png" data-type="png" data-w="469" src="https://mmbiz.qpic.cn/mmbiz_png/TiaRWEtBBEekM9PkX1qlVpVenHH2O7mEeWGM0iaTZLf1ibwrbGIpESDnhyz4PicBUnfmM4sYA4Gxicr6HMCfc6EN9Ww/640?wx_fmt=png"></section><p><span><span>图三</span><span>：</span></span><span>利用</span><span>PRISM</span><span>再利用数据集发现预测性生物标志物</span><span></span></p></section><section powered-by="xiumi.us"><section><section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section></section><section><section powered-by="xiumi.us"><section><section><section powered-by="xiumi.us"><section><img data-ratio="0.1503268" data-src="https://mmbiz.qpic.cn/sz_mmbiz_gif/MVPvEL7Qg0Egj76lSPicXbCTgBVIialdvwWxbm21OZytaf8P6xK86NglUjbFn8agwwLkdNhBNdSRvMLtiaXKjEj7A/640?wx_fmt=gif" data-type="gif" data-w="306" width="100%" src="https://mmbiz.qpic.cn/sz_mmbiz_gif/MVPvEL7Qg0Egj76lSPicXbCTgBVIialdvwWxbm21OZytaf8P6xK86NglUjbFn8agwwLkdNhBNdSRvMLtiaXKjEj7A/640?wx_fmt=gif"></section></section></section></section></section></section><section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section></section></section></section><section powered-by="xiumi.us"><p><span>2021年10月27日，北京生命科学研究所<strong>王晓东</strong>团队在</span><span>Nature Communications上发表名为</span><em><span><strong><span>“Structure of PDE3A-SLFN12 complex and structure-based design for a potent apoptosis inducer of tumor cells”</span></strong></span></em><span>的研究文章，经三种小分子化合物<strong>(anagrelide, nauclefine, DNMDP)</strong>处理后，利用冷冻电镜解析了磷酸二酯酶3A<strong>(PDE3A)</strong>与<strong>Schlafen</strong>蛋白家族<strong>(SLFN)</strong>成员<strong>SLFN12</strong>形成的复合物结构，发现三种小分子均可使两种蛋白质形成PDE3A-SLFN12复合物，进而促进细胞凋亡，基于药代动力学、药效学及安全性等综合考虑，该团队选取了原本用于治疗血小板增多症的上市药物<strong>阿那格雷(anagrelide)</strong>进一步优化改造，结果显示改造后的anagrelide类似物诱导细胞凋亡的活性更高，且小鼠成瘤模型实验中抑制肿瘤生长的能力更强。</span><span></span></p><p><span></span></p></section><section powered-by="xiumi.us"><section><section><section powered-by="xiumi.us"><section><section><section powered-by="xiumi.us"><section><img data-ratio="0.1503268" data-src="https://mmbiz.qpic.cn/sz_mmbiz_gif/MVPvEL7Qg0Egj76lSPicXbCTgBVIialdvwWxbm21OZytaf8P6xK86NglUjbFn8agwwLkdNhBNdSRvMLtiaXKjEj7A/640?wx_fmt=gif" data-type="gif" data-w="306" width="100%" src="https://mmbiz.qpic.cn/sz_mmbiz_gif/MVPvEL7Qg0Egj76lSPicXbCTgBVIialdvwWxbm21OZytaf8P6xK86NglUjbFn8agwwLkdNhBNdSRvMLtiaXKjEj7A/640?wx_fmt=gif"></section></section></section></section></section></section><section><section powered-by="xiumi.us"><section><p><strong>简评</strong></p></section></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section powered-by="xiumi.us"><section><span>PRISM药物再利用资源的建立无疑证明了某些非肿瘤药物直接用于临床试验对癌症患者进行测试是存在可能的，然而即便是已获批上市的临床用药，在转变适应症之前依旧需要确定在人体内可达到且能耐受的浓度范围内针对某种癌症的杀伤活性等指标，利用特定的小鼠动物模型即可在短时间内复制出典型的病理模型，又能避免直接在人体身上进行实验的危险性，从而为临床研究提供可靠依据。总的来说，重新定位现有药物的临床适应症，老药新用，对目前诸如肺鳞癌等缺乏有效靶向药物、致死率高的癌症患者而言不失为一大福音。</span><br></section><p><span><br></span></p><p>                                  <strong> ——袁增壮</strong></p></section></section><section powered-by="xiumi.us"><section><section><section><svg viewbox="0 0 1 1"></svg></section></section><section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section></section></section></section></section></section><section powered-by="xiumi.us"><section><section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section></section><section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section></section></section></section><section powered-by="xiumi.us"><p><br></p><p><em><span><strong>原文链接：</strong></span></em></p><section><span>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328899/</span><span></span></section><p><em><span>点击文末 “阅读原文” 即可查看</span></em><br></p><section powered-by="xiumi.us"><section><section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section></section><section><section powered-by="xiumi.us"><section><section><section powered-by="xiumi.us"><section><img data-ratio="0.1503268" data-src="https://mmbiz.qpic.cn/sz_mmbiz_gif/MVPvEL7Qg0Egj76lSPicXbCTgBVIialdvwWxbm21OZytaf8P6xK86NglUjbFn8agwwLkdNhBNdSRvMLtiaXKjEj7A/640?wx_fmt=gif" data-type="gif" data-w="306" width="100%" src="https://mmbiz.qpic.cn/sz_mmbiz_gif/MVPvEL7Qg0Egj76lSPicXbCTgBVIialdvwWxbm21OZytaf8P6xK86NglUjbFn8agwwLkdNhBNdSRvMLtiaXKjEj7A/640?wx_fmt=gif"></section></section></section></section></section></section><section><section powered-by="xiumi.us"><section><br></section></section></section></section></section><p><span><span><strong>参考文献</strong></span>：</span></p><p><span>1. </span><span>Corsello SM, et al. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling</span><span>. </span><strong><em><span>Nat Cancer</span><span>.</span></em></strong><span> </span><span>Feb</span><span>,</span><span> </span><span>202</span><span>0</span><span>.</span></p><section><span>2. </span><span>Chen J, et al. Structure of PDE3A-SLFN12 complex and structure-based design for a potent apoptosis inducer of tumor cells</span><span>. </span><em><strong><span>Nat Commun.</span></strong></em><span> </span><span>Oct</span><span>,</span><span> </span><span>202</span><span>1<span>.</span></span></section><p><span></span></p></section><section powered-by="xiumi.us"><section><section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section></section><section><section powered-by="xiumi.us"><section><section><section powered-by="xiumi.us"><section><img data-ratio="0.1503268" data-src="https://mmbiz.qpic.cn/sz_mmbiz_gif/MVPvEL7Qg0Egj76lSPicXbCTgBVIialdvwWxbm21OZytaf8P6xK86NglUjbFn8agwwLkdNhBNdSRvMLtiaXKjEj7A/640?wx_fmt=gif" data-type="gif" data-w="306" width="100%" src="https://mmbiz.qpic.cn/sz_mmbiz_gif/MVPvEL7Qg0Egj76lSPicXbCTgBVIialdvwWxbm21OZytaf8P6xK86NglUjbFn8agwwLkdNhBNdSRvMLtiaXKjEj7A/640?wx_fmt=gif"></section></section></section></section></section></section><section><section powered-by="xiumi.us"><section><br></section></section></section></section></section><section powered-by="xiumi.us"><section><span>转载须知</span><br></section><section><span>【原创文章】“肺鳞癌”原创文章，欢迎个人转发分享，未经允许禁止转载，所刊登的所有作品的著作权均为“肺鳞癌”所拥有。“肺鳞癌”保留所有法定权利，违者必究。转载及合作：jianl@intl.zju.edu.cn</span></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><p><span><strong>关于我们</strong></span></p></section></section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section></section><section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section></section></section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section><section powered-by="xiumi.us"><section><p><strong><span>ABOUT US</span></strong></p></section></section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p>本公众号由浙江大学国际校区ZJE-刘坚课题组创办，聚焦于肺鳞癌分子作用机制，关注并发布最新肺鳞癌领域前沿进展，包括诊断、靶向治疗，旨在打造一个良好的肺鳞癌科研共享平台。请关注我们的肺癌三维基因组多组学网站（LungCancer3d.net)。</p></section></section></section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section><section powered-by="xiumi.us"><section><section><section powered-by="xiumi.us"><section><section><br></section></section></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><img data-ratio="1" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/TiaRWEtBBEel5ib3icnQROyeG0daZ3c8xeRED4OXoicjK4q4STaDQdyIFDCeZyAJ5RmjIHeymJgcMTHpelk9y0pFDQ/640?wx_fmt=jpeg" data-type="jpeg" data-w="258" width="100%" src="https://mmbiz.qpic.cn/mmbiz_jpg/TiaRWEtBBEel5ib3icnQROyeG0daZ3c8xeRED4OXoicjK4q4STaDQdyIFDCeZyAJ5RmjIHeymJgcMTHpelk9y0pFDQ/640?wx_fmt=jpeg"></section></section></section><section><section powered-by="xiumi.us"><section><p><strong>扫描二维码</strong><br></p><p><strong><span>立即关注</span></strong><br></p><p><span>微信号 : </span><span>LUSC_2021-</span></p><p><span>邮箱：jianl@intl.zju.edu.cn</span></p></section></section></section></section></section></section></section></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/ZIi7RsGUTCqpMpVTkFoM0w",target="_blank" rel="noopener noreferrer">原文链接</a>
